Négrier C - Search Results

1

Pioneering therapeutic proteins in hemophilia care through innovative technologies.

Pabinger-Fasching I, Négrier C. Pabinger-Fasching I, et al. Among authors: negrier c. Thromb Res. 2016 May;141 Suppl 3:S1. doi: 10.1016/S0049-3848(16)30413-3. Thromb Res. 2016. PMID: 27288062 Free article. No abstract available.

2

Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate.

Guérois C, Laurian Y, Rothschild C, Parquet-Gernez A, Duclos AM, Négrier C, Vicariot M, Fimbel B, Fressinaud E, Fiks-Sigaud M, et al. Guérois C, et al. Among authors: negrier c. Thromb Haemost. 1995 Feb;73(2):215-8. Thromb Haemost. 1995. PMID: 7792732

3

The concept of recombinant factor VIIa megadose for treating bleeding episodes in high-titer inhibitor patients with hemophilia: toward an expanding indication?

Negrier C. Negrier C. J Thromb Haemost. 2003 Mar;1(3):423-4. doi: 10.1046/j.1538-7836.2003.00058.x. J Thromb Haemost. 2003. PMID: 12871444 Free article. No abstract available.

4

Gene therapy for hemophilia? Yes.

Negrier C. Negrier C. J Thromb Haemost. 2004 Aug;2(8):1234-5. doi: 10.1111/j.1538-7836.2004.00934.x. J Thromb Haemost. 2004. PMID: 15304020 Free article. No abstract available.

5

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.

Santagostino E, Negrier C, Klamroth R, Tiede A, Pabinger-Fasching I, Voigt C, Jacobs I, Morfini M. Santagostino E, et al. Among authors: negrier c. Blood. 2012 Sep 20;120(12):2405-11. doi: 10.1182/blood-2012-05-429688. Epub 2012 Aug 2. Blood. 2012. PMID: 22859609 Free PMC article.

6

Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.

Perot E, Enjolras N, Le Quellec S, Indalecio A, Girard J, Negrier C, Dargaud Y. Perot E, et al. Among authors: negrier c. Thromb Res. 2015 May;135(5):1017-24. doi: 10.1016/j.thromres.2015.02.034. Epub 2015 Mar 10. Thromb Res. 2015. PMID: 25795563

7

Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4).

Young G, Collins PW, Colberg T, Chuansumrit A, Hanabusa H, Lentz SR, Mahlangu J, Mauser-Bunschoten EP, Négrier C, Oldenburg J, Patiroglu T, Santagostino E, Tehranchi R, Zak M, Karim FA. Young G, et al. Among authors: negrier c. Thromb Res. 2016 May;141:69-76. doi: 10.1016/j.thromres.2016.02.030. Epub 2016 Mar 2. Thromb Res. 2016. PMID: 26970716 Clinical Trial.

8

Entering new areas in known fields: recombinant fusion protein linking recombinant factor VIIa with recombinant albumin (rVIIa-FP) - advancing the journey.

Négrier C. Négrier C. Thromb Res. 2016 May;141 Suppl 3:S9-S12. doi: 10.1016/S0049-3848(16)30416-9. Thromb Res. 2016. PMID: 27288065 Free article. Review.

9

Simplifying surgery in haemophilia B: Low factor IX consumption and infrequent infusions in surgical procedures with rIX-FP.

Curtin J, Santagostino E, Karim FA, Li Y, Seifert W, Négrier C. Curtin J, et al. Among authors: negrier c. Thromb Res. 2020 Apr;188:85-89. doi: 10.1016/j.thromres.2020.02.011. Epub 2020 Feb 14. Thromb Res. 2020. PMID: 32109773 Free article.

10

Efficacy and safety of rIX-FP in surgery: An update from a phase 3b extension study.

Pan-Petesch B, Nagao A, Karim FA, Tosetto A, Roman MTA, Seifert W, Li Y, Négrier C. Pan-Petesch B, et al. Among authors: negrier c. Thromb Res. 2020 Sep;193:139-141. doi: 10.1016/j.thromres.2020.05.046. Epub 2020 May 28. Thromb Res. 2020. PMID: 32559570 Free article. Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

287 results

Search Page